BUY Piramal Pharma Limited — Kshitija Salvi, Globe Capital Market
byKshitija Salvi, Globe Capital MarketHorizon: NA (inferred Swing (≤2wk))7 Sept 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·8 Sept · today
Piramal Pharma: अमेरिकी टैरिफ के खतरे के बीच कंपनी की नई स्ट्रैटेजी, मुनाफे में दमदार उछाल
NewsGoogle News·5 Sept · 3d ago
Piramal Pharma CDMO Strategy Helps Clients Navigate US Tariff Risks
NewsGoogle News·5 Sept · 3d ago
Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations
NewsGoogle News·26 Aug · 2w ago
2 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · adjacent horizon·26 Aug · 2w ago
US envoy Sergio Gor meets Piramal Group Chairman Ajay Piramal, discusses expansion plans in US
NewsGoogle News·27 Aug · 2w ago
US envoy Sergio Gor meets Piramal Group Chairman Ajay Piramal, discusses expansion plans in US
NewsGoogle News·27 Aug · 2w ago
Piramal Pharma emphasises sustainability in FY 2025-26 report
NewsGoogle News·24 Aug · 2w ago
MACD below its signal line — bearish momentum
Technicals · macd·8 Sept · today
Piramal Pharma reports 22.6% drop in Scope 1 & 2 emissions for FY26
NewsGoogle News·24 Aug · 2w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.